Plain-English translation of NCT07517263 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a long-term safety study for people with heart disease and elevated lipoprotein(a) — a type of cholesterol linked to heart problems. You would continue receiving pelacarsen, an investigational medication that lowers lipoprotein(a), but this time the focus is on making sure the medication remains safe and well-tolerated over an extended period. This trial welcomes people who successfully completed an earlier pelacarsen study and want to continue treatment.
Even after early trials show a drug works, researchers need to understand how it performs over months and years of use. This study exists to gather that long-term safety data and ensure this medication remains a safe option for people with heart disease and high lipoprotein(a).
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive pelacarsen as a 80 mg injection once per month, continuing the treatment you began in the earlier trial. You will attend regular study visits where researchers check your health, monitor how well you tolerate the medication, and watch for any side effects. The study is open-label, meaning both you and your doctor know you are receiving the medication — this is a continuation study designed to follow your safety and well-being over the long term.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States